List view / Grid view
We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.
Delivering Txnip to mice with retinitis pigmentosa was an effective treatment, making this approach a potential gene therapy for the disease.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
Mice with congenital blindness have shown significant improvement in vision after undergoing a new gene therapy.
Researchers have developed a new technique to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa...
Researchers create eye neuron network model to study retinal diseases, possible treatment options...
NIH discovery in mice could lead to therapies to reduce vision loss from diseases of the retina...
22 July 2016 | By Niamh Louise Marriott, Digital Content Producer
ReNeuron Group plc, a UK-based stem cell research company, today revealed further key pre-clinical efficacy data with its human retinal progenitor cells...
8 June 2016 | By Victoria White, Digital Content Producer
The orphan medicinal product designation was granted to AGTC's investigational gene therapy for the treatment XLRP caused by mutations in the RPGR gene...
1 February 2016 | By Victoria White
Astellas and CLINO have entered into a license agreement for the worldwide development and commercialisation of Adeno-associated Virus-modified Volvox channelrhodopsin-1 (AAV-mVChR1)...
27 January 2016 | By Victoria White
The study marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient's tissue...
